ATXI AVENUE THERAPEUTICS, INC. revenue, earnings and financials
For the quarter ended June 30, 2026, AVENUE THERAPEUTICS, INC. reported revenue of $0 (down 100.0% from a year earlier), net income of −$690K and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was $1.40M.
ATXI annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.40M, gross profit n/a, operating income −$3.08M, net income −$2.91M (margin -207.2%), EPS n/a
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$11.3M, net income −$11.7M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$14.5M, net income −$10.5M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$8.04M, net income −$3.55M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$3.74M, net income −$3.73M (margin n/a), EPS −$0.22
ATXI quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$690K, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$695K, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$709K, EPS n/a
- Quarter ended Sep 30, 2025: revenue $0, net income −$683K, EPS n/a
- Quarter ended Jun 30, 2025: revenue $1.40M, net income $335K, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.85M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.54M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $0, net income −$3.08M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $0, net income −$2.69M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$4.34M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $595K, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income $526K, EPS $0.06
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.01M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.60M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income $575K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$662K, EPS −$0.45
- Quarter ended Jun 30, 2022: revenue n/a, net income −$604K, EPS −$0.03
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.86M, EPS −$0.14
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$913K, EPS $0.69
- Quarter ended Sep 30, 2021: revenue n/a, net income −$871K, EPS −$0.79
ATXI cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.83M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$9.03M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$9.45M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow −$7.60M, share buybacks $1.10M
- Fiscal year ended Dec 2021: operating cash flow −$3.75M, share buybacks n/a
ATXI balance sheet
- Jun 30, 2026: cash $1.94M, total assets $1.98M, total liabilities $1.41M, shareholders' equity $569K
- Mar 31, 2026: cash $2.42M, total assets $2.47M, total liabilities $1.27M, shareholders' equity $1.20M
- Dec 31, 2025: cash $2.86M, total assets $2.93M, total liabilities $1.10M, shareholders' equity $1.83M
- Sep 30, 2025: cash $3.71M, total assets $3.73M, total liabilities $1.42M, shareholders' equity $3.56M
- Jun 30, 2025: cash $3.33M, total assets $4.16M, total liabilities $1.33M, shareholders' equity $4.06M
- Mar 31, 2025: cash $3.50M, total assets $3.59M, total liabilities $1.26M, shareholders' equity $3.51M
- Dec 31, 2024: cash $2.59M, total assets $2.67M, total liabilities $816K, shareholders' equity $2.80M
- Sep 30, 2024: cash $2.60M, total assets $2.63M, total liabilities $973K, shareholders' equity $2.61M
What is ATXI's revenue?
AVENUE THERAPEUTICS, INC. reported $1.40M of revenue for the fiscal year ended December 2025.
Is ATXI profitable?
No. AVENUE THERAPEUTICS, INC. lost $2.78M over the last four quarters.